Introduction
============

In 1996, Salkeld et al. \[[@B1]\] found that screening the average-risk Australian population for colorectal cancer using a faecal occult blood test (FOBT), compared to existing practice, would cost \$24,660 per life-year gained (LYG). Due to uncertainty regarding the effectiveness of FOBT screening, they report a range of values, between \$12,695 and \$67,848 per LYG. Randomised controlled trials of population screening with FOBT conducted in the UK \[[@B2]\] and Denmark \[[@B3]\], but published after Salkeld et al.\'s study, have reduced this uncertainty. The cost-effectiveness analyses based on the UK trial data \[[@B4]\] suggest a cost per life-year gained between £1,371--£5,685 (approximately \$AU3,370--13,974) and the analysis of the Danish trial data \[[@B5]\] suggest a cost per life-year gained between 17,000--42,000DKK (approximately \$AU3,916--9,672).

Three years before publication of Salkeld\'s study Bolin \[[@B6]\] discussed the advantages of using colonoscopy for population screening, and in 1996, he suggested colonoscopy was cost-effective \[[@B7]\]. In 1997, he asked whether the time had come to use colonoscopy for population screening in Australia \[[@B8]\]. Kermond \[[@B9]\] responded suggesting double contrast barium enema (DCBE) should not be overlooked arguing colonoscopy is 10 times more expensive, false negatives still occur and complication rates are higher. Bolin argued, in the same issue of the MJA, that the sensitivity of colonoscopy exceeds DCBE, the complication rate is only 0.1% and cost differentials are actually less than those suggested by Kermond \[[@B9]\].

Bolin also claimed that FOBT at one and three years and colonoscopy at 10 years, assuming a 10-year period during which time the cancer is detectable and curable (known as the dwell time), are cost-effective modes of CRC screening, probably referring to data subsequently published in 1999 \[[@B10]\]. For this research, the authors substituted Australian values for cost parameters into a US model of the cost-effectiveness of CRC screening \[[@B11]\] and generalised the results to the Australian population. They reported change in cost and change in life-years gained, as compared to existing practice, for competing screening strategies that encompass FOBT, colonoscopy, flexible sigmoidoscopy and DCBE \[[@B10]\]. By assuming that society is willing to pay up to \$US40,000 (approximately \$AU65,449 in 2002 prices) per LYG, Bolin proposed that annual FOBT, triennial FOBT, triennial DCBE, five-yearly DCBE, five-yearly colonoscopy and ten-yearly colonoscopy are all cost-effective and concluded that physicians have the option of offering individuals a range of screening alternatives, including colonoscopy \[[@B10]\]. Since publishing the research Bolin has argued, on four separate occasions that population screening with colonoscopy is cost-effective \[[@B12]-[@B15]\]. The last of these, in 2002 \[[@B14]\], provoked Macrae and Hebbard \[[@B16]\] to criticise Bolin\'s interpretation of epidemiological data.

In 2004, O\'Leary et al. \[[@B17]\] also addressed the economic questions around population screening in Australia. They estimated the cost-effectiveness, compared to existing practice, of FOBT, flexible sigmoidoscopy and colonoscopy, and found flexible sigmoidoscopy and colonoscopy were cost-effective but FOBT was not.

There are important differences in the way that Salkeld et al. \[[@B1]\], Bolin et al. \[[@B10]\] and O\'Leary et al. \[[@B17]\] report the Australian cost and effectiveness data. Salkeld et al. reports an incremental cost-effectiveness ratio, O\'Leary et al. reports both average and incremental cost-effectiveness ratios, however they draw their conclusions from an average analysis. Bolin only calculates average cost-effectiveness ratios. The correct ratio for decision-making is an incremental cost-effectiveness ratio: McMahon \[[@B18]\] argues the use of average ratios is not meaningful; Drummond \[[@B19]\] and Gold \[[@B20]\] both discuss why incremental rather than average cost-effectiveness ratios are relevant for decision making; and, both Torgerson \[[@B21]\] and Neuhauser & Lewicki \[[@B22]\] provide examples of how average analyses muddy the waters. In their much-cited 1975 paper, Neuhauser & Lewicki \[[@B22]\] reviewed data on screening for CRC. They illustrated that repeatedly testing a stool sample up to six times, when a previous test result was negative, would capture all cases of CRC, at an average cost per case of \$2451. They also did an incremental analysis, with the same data, and showed the incremental cost per case detected, from the fifth to sixth round of testing was \$47 million. This illustrates that average analyses can be grossly misleading.

We have four objectives in this paper: first, to demonstrate why incremental, not average, cost-effectiveness ratios should be used for decision-making; second, to update the cost data reported by Salkeld et al. \[[@B1]\], Bolin et al. \[[@B10]\] and O\'Leary et al. \[[@B17]\] to 2002 Australian dollar prices; third, to calculate incremental cost-effectiveness ratios from the Bolin data; and fourth, to discuss the results of our re-analysis, comparing the outcomes from the three previous studies. This will provide readers with an up-to-date and appropriate assessment of the existing cost-effectiveness data for population-based CRC screening programmes in Australia.

Defining average & incremental cost-effectiveness ratios
========================================================

Average cost-effectiveness ratios for health care interventions are the amounts by which costs change from a baseline comparator (Δ*C*) divided by the amount by which health benefits change from a baseline comparator (Δ*E*). The baseline comparator is often existing practice. We illustrate this method with hypothetical data in Table [1](#T1){ref-type="table"} by presenting the change in costs and health effects that arise from four competing health care alternatives. If we remain with Existing Practice, there is no change in cost or health effect. However, if we are committed to generating health effects and we wish to be efficient, then we should choose the cheapest option that improves health outcomes. The data in Table [1](#T1){ref-type="table"} show that Intervention 4 generates the best ratio of (Δ*C*) and (Δ*E*) when compared to Existing Practice. Cost changes by \$145,000 and health effects change by 150 and the cost per LYG is \$967.

###### 

An illustration of average cost-effectiveness ratios for four competing hypothetical health care interventions

                      Change in cost (\$)   Change in health effect (Life-years Gained)   Average cost-effectiveness (\$)
  ------------------- --------------------- --------------------------------------------- ---------------------------------
                      (Δ*C*)                (Δ*E*)                                        (Δ*C*) divided by (Δ*E*)
                                                                                          
  Existing Practice   0                     0                                             
  Intervention 1      200,000               12                                            16,667
  Intervention 2      75,000                15                                            5,000
  Intervention 3      300,000               250                                           1,200
  Intervention 4      145,000               150                                           967

We reject Interventions 1 and 2. The reasons lie in Figure [1](#F1){ref-type="fig"} (which is a graph of the data in Table [1](#T1){ref-type="table"}). Intervention 1 generates less health benefit and higher costs than Intervention 4, a situation described as \'simple dominance\'. For this comparison, Intervention 4 is preferred on both costs and outcomes. Intervention 2 also generates less health effect but differs from Intervention 1 in that it\'s cheaper than Intervention 4; however, the cost per LYG from Intervention 2 is greater than the cost per LYG from Intervention 4. This situation is known as \'extended dominance\' and is only relevant if the cost of Intervention 4 (\$145,000) exceeds the total amount of money available to the decision-maker. Rather than choosing Intervention 2 over Intervention 4, it would be better (more productively efficient) to choose some blend of existing practice and Intervention 4. This implies that some proportion of the population would receive Intervention 4 and the remainder would receive existing practice. This raises questions of equity of access and so poses another set of problems for decision-makers. If the available budget exceeds \$145,000, there is a further question to consider. Do we invest in the more costly but more effective Intervention 3? Some care is required when making this decision. The average cost-effectiveness ratio for Intervention 3 (\$1,200 per LYG), represented by the dashed line on Figure [1](#F1){ref-type="fig"}, is misleading. It\'s calculated by comparing Intervention 3 to existing practice; yet, the relevant decision is whether we should invest in Intervention 3 given that we have established Intervention 4 as the most cost-effective option. We must consider the incremental changes in cost and health effects compared to the next best alternative, Intervention 4. The incremental cost-effectiveness ratios for Interventions 4 and 3 are marked with solid lines on Figure [1](#F1){ref-type="fig"}. When a more effective alternative also costs more, then the decision-maker must compare the increased cost with the increased effects \[[@B19]\]. The only way to achieve this is to conduct an incremental analysis, which we illustrate in Table [2](#T2){ref-type="table"}. Investing in Intervention 3, as compared to 4, changes total costs by \$155,000 and LYG by 100, yielding an incremental cost-effectiveness ratio of \$1,550 per LYG not the \$1,200 per LYG as previously estimated using average cost-effectiveness ratios and illustrated in Table [1](#T1){ref-type="table"}.

###### 

An illustration of average and incremental cost-effectiveness ratios for the two remaining hypothetical health care interventions

  Intervention        Cost (\$)   Incremental changes in cost (\$)   Effectiveness (LYG)   Incremental changes in effectiveness (LYG)   Average cost-effectiveness ratio (\$)   Incremental cost-effectiveness ratio (\$)
  ------------------- ----------- ---------------------------------- --------------------- -------------------------------------------- --------------------------------------- -------------------------------------------
                      **(a)**     **(b)**                            **(c)**               **(d)**                                      **(a)/(c)**                             **(b)/(d)**
                                                                                                                                                                                
  Existing Practice   0                                              0                                                                                                          
  Intervention 4      145,000     145,000                            150                   150                                          967                                     967
  Intervention 3      300,000     155,000                            250                   100                                          1,200                                   1,550

Note: Interventions 1 and 2 have been rejected on the grounds of \'simple\' and \'extended\' dominance, see text for a discussion

![Change in cost and change in effect from four hypothetical health care interventions.](1743-8462-2-10-1){#F1}

Imagine you have decided to take a holiday in a beach resort. You face a decision between a standard apartment for \$1,000 and a Penthouse apartment for \$1,300. Because you have decided to take the holiday (and so one of the apartments), it is the difference in cost (\$300) that you compare to the difference in benefit (penthouse vs. standard apartment). If you don\'t perceive the additional benefit to be worth the extra \$300, then you reject the penthouse. This simple example illustrates the importance of thinking about decisions in terms of incremental changes. An average analysis with both options compared to \'no holiday\' may lead to a bad decision.

Methods for re-analysis and the results
=======================================

We converted Bolin\'s \$US dollar estimates to Australian dollars with the exchange rate reported in the original article \[[@B10]\] and adjusted the estimates reported by Bolin, Salkeld and O\'Leary to 2002 prices using a health price index \[[@B23]\]. As Salkeld and O\'Leary reported incremental cost-effectiveness ratios, we only need to calculate incremental cost-effectiveness ratios from the Bolin data. We achieved this by inputting the reported estimates of (Δ*C*) and (Δ*E*) into decision analysis software \[[@B24]\]. Assuming a 5-year dwell time (the period during which cancer can be detected and cured), we include 13 screening strategies and the existing practice comparator. For a 10-year dwell time, estimates of (Δ*C*) and (Δ*E*)were reported for different, additional, frequencies of FOBT, flexible sigmoidoscopy and DCBE screening, resulting in 27 strategies and the existing practice comparator. We ranked all strategies by increasing cost, estimated incremental cost and effectiveness, and excluded all strategies for which other options prevailed on the basis of \'simple\' or \'extended\' dominance. Finally, we reported the strategies not excluded due to either \'simple\' or \'extended\' dominance and present the relevant incremental cost-effectiveness ratios.

In Table [3](#T3){ref-type="table"}, we describe all strategies evaluated by the authors of the three studies.

###### 

Descriptions of the screening strategies included in the re-analysis

  Screening strategy   Description of screening strategy                                           Salkeld \[1\]   Bolin \[10\] (5-year dwell time)   Bolin \[10\] (10-year dwell time)   O\'Leary \[17\]
  -------------------- --------------------------------------------------------------------------- --------------- ---------------------------------- ----------------------------------- -----------------
  Existing practice    Existing screening practices                                                                X                                  X                                   X
  COL10                10-yearly colonoscopy                                                                       X                                  X                                   X
  COL5                 5-yearly colonoscopy                                                                        X                                  X                                   
  COL                  one off screening colonoscopy at age 50                                                     X                                  X                                   
  DCBE                 one off double contrast barium enema                                                                                           X                                   
  DCBE10               10-yearly double contrast barium enema                                                                                         X                                   
  DCBE15               15-yearly double contrast barium enema                                                                                         X                                   
  DCBE20               20-yearly double contrast barium enema                                                                                         X                                   
  DCBE3                3-yearly double contrast barium enema                                                       X                                  X                                   
  DCBE5                5-yearly double contrast barium enema                                                       X                                  X                                   
  FOBT10               10-yearly faecal occult blood test                                                                                             X                                   
  FOBT15               15-yearly faecal occult blood test                                                                                             X                                   
  FOBT2                2-yearly faecal occult blood test                                                                                              X                                   X
  FOBT20               20-yearly faecal occult blood test                                                                                             X                                   
  FOBT5                5-yearly faecal occult blood test                                                                                              X                                   
  FOBT                 one off faecal occult blood test                                                                                               X                                   
  FOBT1                annual faecal occult blood test                                             X               X                                  X                                   X
  FOBT1+DCBE3          annual faecal occult blood test and 3-yearly double contrast barium enema                   X                                  X                                   
  FOBT1+DCBE5          annual faecal occult blood test and 5-yearly double contrast barium enema                   X                                  X                                   
  FOBT1+FSIG3          annual faecal occult blood test and 3-yearly flexible sigmoidoscopy                         X                                  X                                   
  FOBT1+FSIG5          annual faecal occult blood test and 5-yearly flexible sigmoidoscopy                         X                                  X                                   
  FOBT3                3-yearly faecal occult blood test                                                           X                                  X                                   
  FSIG                 flexible sigmoidoscopy once only                                                                                               X                                   
  FSIG10               10-yearly flexible sigmoidoscopy                                                                                               X                                   X
  FSIG15               15-yearly flexible sigmoidoscopy                                                                                               X                                   
  FSIG20               20-yearly flexible sigmoidoscopy                                                                                               X                                   
  FSIG3                3-yearly flexible sigmoidoscopy                                                             X                                  X                                   
  FSIG5                5-yearly flexible sigmoidoscopy                                                             X                                  X                                   

In Figure [2](#F2){ref-type="fig"}, we illustrate the costs and effects of all strategies reported by Bolin, assuming a 5-year dwell time. The strategies to the left and above the cost-effective frontier, defined by the solid line, are excluded by either \'simple\' or \'extended\' dominance. The three remaining (un-dominated) strategies, that define the cost-effective frontier, are EXISTING PRACTICE, DCBE3 and FOBT1+DBCE3. In Table [4](#T4){ref-type="table"}, we report all corresponding costs, health benefits and cost-effectiveness ratios, and indicate the options that are \'simply\' dominated. In Table [5](#T5){ref-type="table"}, we report the incremental cost-effectiveness ratios for the options that survive the tests of \'simple\' or \'extended\' dominance; these options define the cost-effective frontier.

![Updated costs and effects for Bolin et al\'s 13 tested strategies, assuming a five-year dwell time.](1743-8462-2-10-2){#F2}

###### 

Estimates of costs in 2002 prices, health benefits and cost-effectiveness from Bolin *et al*. \[10\], assuming a five-year dwell time

  Strategy            Cost (\$)     Incremental changes in cost (\$)   Effectiveness (LYG)   Incremental changes in effectiveness (LYG)   Average cost-effectiveness ratio (\$)   Incremental cost-effectiveness ratio (\$)
  ------------------- ------------- ---------------------------------- --------------------- -------------------------------------------- --------------------------------------- -------------------------------------------
                      **(a)**       **(b)**                            **(c)**               **(d)**                                      **(a)/(c)**                             **(b)/(d)**
                                                                                                                                                                                  
  EXISTING PRACTICE   0                                                0                                                                  (Undefined)                             
  FOBT3               109,167,314   109,167,314                        2,010                 2,010                                        54,312                                  54,312
  COL                 195,987,062   86,819,748                         1,166                 -844                                         168,085                                 (Simply Dominated)
  FSIG5               205,570,434   96,403,120                         3,365                 1,355                                        61,091                                  71,146
  FOBT1               230,156,355   24,585,921                         4,447                 1,082                                        51,755                                  22,723
  DCBE5               253,881,621   23,725,266                         5,050                 603                                          50,274                                  39,345
  FSIG3               271,052,169   17,170,548                         3,909                 -1,141                                       69,341                                  (Simply Dominated)
  COL10               278,701,522   24,819,901                         3,718                 -1,332                                       74,960                                  (Simply Dominated)
  DCBE3               307,911,416   54,029,795                         6,184                 1,134                                        49,792                                  47,645
  COL5                360,264,079   52,352,663                         6,181                 -3                                           58,286                                  (Simply Dominated)
  FOBT1+FSIG5         364,595,167   56,683,751                         5,849                 -335                                         62,335                                  (Simply Dominated)
  FOBT1+DCBE5         373,803,843   65,892,427                         6,573                 389                                          56,870                                  169,389
  FOBT1+FSIG3         420,786,416   46,982,573                         6,032                 -541                                         69,759                                  (Simply Dominated)
  FOBT1+DBCE3         424,911,339   51,107,496                         7,020                 447                                          60,529                                  114,334

###### 

Incremental cost-effectiveness ratios in 2002 prices for the preferred (not dominated) strategies from Bolin et al. \[10\], assuming a five-year dwell time

  Strategy            Cost (\$)     Incremental changes in cost (\$)   Effectiveness (LYG)   Incremental changes in effectiveness (LYG)   Average cost-effectiveness ratio (\$)   Incremental cost-effectiveness ratio (\$)
  ------------------- ------------- ---------------------------------- --------------------- -------------------------------------------- --------------------------------------- -------------------------------------------
                      **(a)**       **(b)**                            **(c)**               **(d)**                                      **(a)/(c)**                             **(b)/(d)**
                                                                                                                                                                                  
  EXISTING PRACTICE   0                                                0                                                                  (Undefined)                             
  DCBE3               307,911,416   307,911,416                        6,184                 6,184                                        49,792                                  49,792
  FOBT1+DBCE3         424,911,339   116,999,923                        7,020                 836                                          60,529                                  139,952

Note: Other options rejected on the grounds of \'simple\' and \'extended\' dominance, see text for a discussion.

In Figure [3](#F3){ref-type="fig"}, we illustrate the costs and effects for all strategies reported by Bolin, assuming a 10-year dwell time. In this case EXISTING PRACTICE, FOBT2, DCBE5, DCBE3, FOBT1+DCBE5 and FOBT1+DCBE3 define the cost-effective frontier. In Table [6](#T6){ref-type="table"}, we report all corresponding costs, health benefits and cost-effectiveness ratios, and indicate the options that are \'simply\' dominated. In Table [7](#T7){ref-type="table"}, we report the incremental cost-effectiveness ratios for the options that survive the tests of \'simple\' or \'extended\' dominance; again, these options define the cost-effective frontier.

###### 

Estimates of costs in 2002 prices, health benefits and cost-effectiveness from Bolin *et al*. \[10\], assuming a 10-year dwell time

  Strategy            Cost (\$)     Incremental changes in cost (\$)   Effectiveness (LYG)   Incremental changes in effectiveness (LYG)   Average cost-effectiveness ratio (\$)   Incremental cost-effectiveness ratio (\$)
  ------------------- ------------- ---------------------------------- --------------------- -------------------------------------------- --------------------------------------- -------------------------------------------
                      **(a)**       **(b)**                            **(c)**               **(d)**                                      **(a)/(c)**                             **(b)/(d)**
                                                                                                                                                                                  
  EXISTING PRACTICE   0                                                0                                                                  (Undefined)                             
  FOBT                24,429,089    24,429,089                         352                   352                                          69,401                                  69,401
  FOBT20              31,633,953    7,204,864                          558                   206                                          56,692                                  34,975
  FOBT15              37,620,230    5,986,277                          681                   123                                          55,243                                  48,669
  FOBT10              47,472,852    9,852,622                          951                   270                                          49,919                                  36,491
  FOBT5               75,561,379    28,088,527                         1,674                 723                                          45,138                                  38,850
  FSIG                102,900,905   27,339,526                         1,222                 -452                                         84,207                                  (Simply Dominated)
  FOBT3               105,521,804   29,960,425                         2,605                 931                                          40,507                                  32,181
  FSIG20              120,362,301   14,840,497                         1,892                 -713                                         63,616                                  (Simply Dominated)
  FSIG15              131,780,307   26,258,503                         2,294                 -311                                         57,446                                  (Simply Dominated)
  DCBE                134,697,657   29,175,853                         1,896                 -709                                         71,043                                  (Simply Dominated)
  FOBT2               140,117,791   34,595,987                         3,551                 946                                          39,459                                  36,571
  FSIG10              148,850,170   8,732,379                          3,127                 -424                                         47,602                                  (Simply Dominated)
  DCBE20              158,390,199   18,272,408                         2,939                 -612                                         53,893                                  (Simply Dominated)
  DCBE15              173,448,383   33,330,592                         3,566                 15                                           48,639                                  2,222,039
  COL                 190,862,405   17,414,022                         2,368                 -1,198                                       80,601                                  (Simply Dominated)
  DCBE10              194,089,298   20,640,915                         4,778                 1,212                                        40,621                                  17,030
  FSIG5               204,328,539   10,239,241                         3,583                 -1,195                                       57,027                                  (Simply Dominated)
  FOBT1               224,367,390   30,278,092                         5,271                 493                                          42,566                                  61,416
  DCBE5               248,112,291   23,744,901                         6,023                 752                                          41,194                                  31,576
  COL10               265,297,565   17,185,274                         5,970                 -53                                          44,438                                  (Simply Dominated)
  FSIG3               270,484,399   22,372,108                         3,993                 -2,030                                       67,740                                  (Simply Dominated)
  DCBE3               304,301,903   56,189,612                         6,720                 697                                          45,283                                  80,616
  COL5                357,822,831   53,520,928                         6,583                 -137                                         54,356                                  (Simply Dominated)
  FOBT1+FSIG5         361,026,560   56,724,657                         6,344                 -376                                         56,908                                  (Simply Dominated)
  FOBT1+DCBE5         370,181,240   65,879,337                         7,076                 356                                          52,315                                  185,054
  FOBT1+FSIG3         417,677,588   47,496,348                         6,457                 -619                                         64,686                                  (Simply Dominated)
  FOBT1+DCBE3         422,777,702   52,596,462                         7,299                 223                                          57,923                                  235,859

###### 

Incremental cost-effectiveness ratios in 2002 prices for the preferred (not dominated) strategies from Bolin et al. \[10\], assuming a 10-year dwell time

  Strategy            Cost (\$)     Incremental changes in cost (\$)   Effectiveness (LYG)   Incremental changes in effectiveness (LYG)   Average cost-effectiveness ratio (\$)   Incremental cost-effectiveness ratio (\$)
  ------------------- ------------- ---------------------------------- --------------------- -------------------------------------------- --------------------------------------- -------------------------------------------
                      **(a)**       **(b)**                            **(c)**               **(d)**                                      **(a)/(c)**                             **(b)/(d)**
                                                                                                                                                                                  
  EXISTING PRACTICE   0                                                0                                                                  (Undefined)                             
  FOBT2               140,117,791   140,117,791                        3,551                 3,551                                        39,459                                  39,459
  DCBE5               248,112,291   107,994,500                        6,023                 2,472                                        41,194                                  43,687
  DCBE3               304,301,903   56,189,612                         6,720                 697                                          45,283                                  80,616
  FOBT1+DCBE5         370,181,240   65,879,337                         7,076                 356                                          52,315                                  185,054
  FOBT1+DCBE3         422,777,702   52,596,462                         7,299                 223                                          57,923                                  235,859

Note: Other options rejected on the grounds of \'simple\' and \'extended\' dominance, see text for a discussion

![Updated costs and effects for Bolin et al\'s 27 tested strategies, assuming a ten-year dwell time.](1743-8462-2-10-3){#F3}

The incremental cost-effectiveness ratio derived from the Salkeld data, in 2002 prices, for FOBT, is \$30,556 per LYG, and the 2002 incremental cost-effectiveness ratios from the O\'Leary data are \$17,356 per LYG for FSIG and \$26,587 per LYG for COL.

These results define the screening options that are preferred (ie, not dominated), by the measure of cost-effectiveness, for population-based CRC screening in Australia. However, the decision over which to choose depends on additional factors that we discuss next.

Discussion
==========

We defined average and incremental cost-effectiveness ratios and emphasise the latter are relevant for decision-making. We calculated incremental cost-effectiveness ratios, in 2002 prices, for a number of population screening strategies, for which Bolin had previously reported average cost-effectiveness ratios. For Bolin\'s estimates of (Δ*C*) and (Δ*E*), for a 5-year dwell time, we found only DCBE3 (\$49,792 per LYG) and FOBT1+DCBE3 (\$139,952 per LYG) were preferred (not dominated). For a 10-year dwell time, FOBT2 (\$39,459 per LYG), DCBE5 (\$43,687 per LYG), DCBE3 (\$80,616 per LYG), FOBT1+DCBE5 (\$185,054 per LYG) and FOBT1+DCBE3 (\$235,859 per LYG) were preferred (not dominated).

Incremental cost-effectiveness ratios are useful for decision-making when a ceiling value for a LYG is specified. Bolin argued in 1996 \[[@B7]\] that \$US40,000 per LYG was the relevant cut-off (approximately \$AU65,449 in 2002 prices). We prefer a decision rule described by Garber & Phelps \[[@B25]\] that states a LYG is worth approximately twice the median annual per capita income. They derived this value from a model of optimal lifetime spending for medical care and explored its relationship to the cost-effectiveness criterion. They evaluated the model in terms of maximizing utility for individuals, with utility a function of income and health. Their rule implies, for Australia, a rational cut-off for one LYG is approximately \$AU39,000 \[[@B26]\].

If we apply this rule to our interpretation of Bolin\'s data, we wouldn\'t recommend any additional population screening activities for the 5-year dwell time, and for a 10-year dwell time, we would only recommend FOBT2. Based on the O\'Leary and Salkeld data we recommend COL and FOBT1, respectively. The results in Tables [4](#T4){ref-type="table"} and [6](#T6){ref-type="table"} illustrate the colonoscopy strategies, championed by Bolin, would cause between 33 and 1,322 years of life to be lost and between \$M17 and \$M87 to be wasted. We showed that all colonoscopy options were dominated by more cost-effective alternatives.

Despite our re-analysis, the decision over which model of CRC screening is optimal for the Australian, average-risk population remains ambiguous. While the incremental cost-effectiveness ratios from two studies support annual FOBT \[[@B1]\] or biennial FOBT \[[@B10]\], the most recent study supports colonoscopy \[[@B17]\]. At least we now have incremental cost-effectiveness ratios in 2002 prices. While two of the studies agree that FOBT screening is preferred, we have not investigated why the O\'Leary \[[@B17]\] analysis leads to a different conclusion. The answer may be sought in a careful assessment of model structures, the particular perspectives adopted for each analysis and the values used for the parameters, which is beyond the scope of this commentary. In addition, we haven\'t attempted to model the effect of uncertainty on the conclusions. This would require access to the models, data and software used in each of the previous three studies. Policy-makers should review the three papers and make a judgement over which they believe produces the best estimates of change in cost and health benefit, identify their willingness to pay for the proposed health benefits and make their decision in the context of other logistic, social and political issues.
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